Thiogenesis Therapeutics Corp (TSE:TTI)

:TTI

TTI

Thiogenesis Therapeutics Corp

RESEARCH TOOLSreports

Want to see TSE:TTI full AI Analyst Report?

Thiogenesis Therapeutics Corp (TTI) Price & Analysis

5 Followers

TTI Stock Chart & Stats

C$0.61

Market closed

C$0.61

Day’s Range― - ―

52-Week RangeC$0.44 - C$0.88

Previous CloseN/A

VolumeN/A

Average Volume (3M)27.61K

Market Cap

C$29.55M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.27

Next Earnings

May 21, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding51,835,957

10 Day Avg. Volume25,970

30 Day Avg. Volume27,615

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.68

Revenue Forecast (FY)C$53.00M

Thiogenesis Therapeutics Corp News

Thiogenesis Advances Cystinosis Program With New Study and Phase 3 Plans for TTI-0102

An announcement from Thiogenesis Therapeutics Corp ( ($TSE:TTI) ) is now available. Thiogenesis Therapeutics has initiated an investigator-initiated...

4M ago

Thiogenesis Posts Positive Phase 2 MELAS Data, Backs Weight-Based Dosing for Lead Mitochondrial Drug

Thiogenesis Therapeutics Corp ( ($TSE:TTI) ) has provided an announcement. Thiogenesis Therapeutics reported interim Phase 2 EU data...

4M ago

Thiogenesis to Present Late-Breaking Phase 2 MELAS Data on TTI-0102 at Mitocon 2026

Thiogenesis Therapeutics Corp ( ($TSE:TTI) ) has provided an announcement. Thiogenesis Therapeutics announced that its abstract detailing preliminary...

4M ago

Thiogenesis to Showcase Mitochondrial Disease Clinical Progress at UMDF Webinar

Thiogenesis Therapeutics Corp ( ($TSE:TTI) ) just unveiled an update. Thiogenesis Therapeutics announced that CEO Patrice Rioux will...

4M ago

Thiogenesis Therapeutics Announces Phase 3 Trial for Innovative Cystinosis Treatment

Thiogenesis Therapeutics Corp ( ($TSE:TTI) ) just unveiled an announcement. Thiogenesis Therapeutics Corp has announced plans to initiate...

6M ago

Thiogenesis Reports Positive Interim Results and Pipeline Advancements

Thiogenesis Therapeutics Corp ( ($TSE:TTI) ) has shared an announcement. Thiogenesis Therapeutics Corp announced positive interim results from...

7M ago

Thiogenesis Therapeutics Advances in MELAS Treatment with TTI-0102 Study

Thiogenesis Therapeutics Corp (($TSE:TTI)) announced an update on their ongoing clinical study. Study Overview: Thiogenesis Therapeutics Corp is...

7M ago

TTI

Thiogenesis Therapeutics Advances LSS Treatment with New TTI-0102 Study

Thiogenesis Therapeutics Corp (($TSE:TTI)) announced an update on their ongoing clinical study. Thiogenesis Therapeutics Corp is advancing its...

7M ago

TTI

Thiogenesis Extends Investor Relations Agreement with Capital Analytica

Thiogenesis Therapeutics Corp ( ($TSE:TTI) ) has issued an announcement. Thiogenesis Therapeutics Corp has announced the extension of...

8M ago

Thiogenesis Therapeutics Reports AGM Results and Corporate Milestones

Thiogenesis Therapeutics Corp ( ($TSE:TTI) ) just unveiled an update. Thiogenesis Therapeutics Corp recently held its Annual General...

8M ago

TTI FAQ

What was Thiogenesis Therapeutics Corp’s price range in the past 12 months?

Thiogenesis Therapeutics Corp lowest stock price was C$0.44 and its highest was C$0.88 in the past 12 months.

What is Thiogenesis Therapeutics Corp’s market cap?

Thiogenesis Therapeutics Corp’s market cap is C$29.55M.

When is Thiogenesis Therapeutics Corp’s upcoming earnings report date?

Thiogenesis Therapeutics Corp’s upcoming earnings report date is May 21, 2026 which is in 2 days.

How were Thiogenesis Therapeutics Corp’s earnings last quarter?

Currently, no data Available

Is Thiogenesis Therapeutics Corp overvalued?

According to Wall Street analysts Thiogenesis Therapeutics Corp’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Thiogenesis Therapeutics Corp pay dividends?

Thiogenesis Therapeutics Corp does not currently pay dividends.

What is Thiogenesis Therapeutics Corp’s EPS estimate?

Thiogenesis Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Thiogenesis Therapeutics Corp have?

Thiogenesis Therapeutics Corp has 51,835,957 shares outstanding.

What happened to Thiogenesis Therapeutics Corp’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Thiogenesis Therapeutics Corp?

Currently, no hedge funds are holding shares in TSE:TTI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Thiogenesis Therapeutics Corp

Thiogenesis Therapeutics Corp is an early stage biotech company. It is developing novel drug formulations that act as precursors to cysteamine, which is a small aminothiol compound that is endogenous in humans in small quantities.